March 20, 2026. 20 items curated for clinical relevance.
Above Threshold
Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
Alabama’s medical cannabis program is preparing to begin retail sales in spring 2026, affecting clinicians’ ability to recommend cannabis products to qualifying patients in the state.
Read more →Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
A study investigates CBD and CBG’s potential therapeutic effects on fatty liver disease, relevant for clinicians considering cannabinoid applications in hepatic conditions.
Read more →From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
This article examines regulatory enforcement actions against cannabis beverage companies, highlighting FDA oversight challenges and compliance risks relevant to clinical practice and patient safety considerations.
Read more →Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
Recent research indicates CBD and CBG may reduce hepatic steatosis and improve metabolic markers, providing clinicians with potential therapeutic targets for managing cannabis-related liver health concerns in patients.
Read more →New Top Cannabis Regulator Sets Priorities In First Board Meeting
A new cannabis regulator outlined their policy priorities at an initial board meeting, establishing foundational direction for industry oversight and clinical practice standards.
Read more →Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
Brazil implements new cannabis regulations affecting medical access and clinical practice, requiring clinicians to understand updated legal frameworks and their impact on patient care delivery.
Read more →2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
Two Greater Cincinnati breweries are challenging Ohio’s ban on THC-infused beverages, raising legal and regulatory questions relevant to cannabis product classification and state-level THC market restrictions.
Read more →New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
Ohio’s new law restricts THC-infused beverage distribution in retail locations, affecting product availability and clinical considerations for patient access and dosing recommendations.
Read more →Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
Oregon legislators failed to pass a bill restricting THC potency in cannabis edibles, leaving higher-dose products available and relevant to clinician counseling on dosing risks and patient safety.
Read more →Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
CBD and CBG demonstrate potential to reduce hepatic steatosis and improve metabolic parameters, offering possible therapeutic applications for cannabis clinicians treating patients with fatty liver disease.
Read more →Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
This article examines formulation and fabrication methods for delivering cannabinoids through oral mucosal tissues, relevant to clinicians seeking alternative administration routes beyond smoking or standard ingestion.
Read more →Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
CBD-dominant cannabis products demonstrate clinical efficacy for anxiety treatment, providing evidence-based therapeutic applications relevant to clinician prescribing decisions and patient care protocols.
Read more →Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
Cannabis extracts demonstrated significant pain reduction in myofascial pain clinical trials, providing clinicians evidence-based data for treating this common musculoskeletal condition.
Read more →The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
This article covers weekly cannabis legal and regulatory updates from March 2026, relevant for clinicians needing current information on changing laws and compliance requirements affecting clinical practice.
Read more →Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
Marijuana gummies sold in Ohio were recalled, requiring clinicians to monitor patients for potential adverse effects and advise them on product safety concerns.
Read more →New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
A new organization is forming to prepare for upcoming Medicare cannabidiol pilot programs, which could expand clinical access to CBD for Medicare beneficiaries.
Read more →Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
This archive covers legal prohibition statuses of marijuana across jurisdictions, providing clinicians essential reference material for understanding regulatory frameworks affecting patient care and prescription guidelines.
Read more →Digest-Level Clinical Commentary
These items reflect a field at an inflection point where rigorous hepatoprotective and anxiolytic evidence is finally matching clinical intuition, yet the regulatory landscape remains fractured by potency debates and interstate commerce conflicts that undermine the standardization necessary for evidence-based prescribing. The convergence of emerging liver disease data with established anxiety and pain efficacy suggests I should be counseling patients on cannabinoid-specific outcomes rather than whole-plant generalities, while simultaneously acknowledging that legislative battles over THC caps and beverage access signal continued policy resistance to nuanced dosing science. What’s clinically actionable here is that formulation standardization and oral delivery innovation are advancing faster than our regulatory frameworks, creating a gap where informed dosing conversations with patients become even more essential.
These items reflect a maturing cannabis market increasingly focused on clinical applications and regulatory standardization, with particular emphasis on metabolic and pain management indications supported by emerging evidence. The concurrent regulatory discussions around potency caps and product formulation suggest policymakers are grappling with how to balance consumer access against public health considerations as the industry expands from illicit markets into mainstream retail channels. The prevalence of research on specific cannabinoid profiles like CBD and CBG indicates a shift toward component-based therapeutic approaches rather than whole-plant formulations in clinical practice.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
FAQ
This News item was assembled from structured source metadata and pipeline scoring.
Have thoughts on this? Share it:
